Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Eur J Neurol ; 15(2): 150-5, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18093154

ABSTRACT

Bilateral temporo-parietal hypoperfusion and decreased glucose metabolism are characteristic in vivo findings in Alzheimer's disease (AD). Lactate is a metabolic vasodilator and is known to induce increased cerebral blood flow in healthy adults. The present study addresses the issue whether sodium lactate infusion affects functional state and resulting electroencephalographic patterns of AD patients. Twelve late-onset sporadic AD probands participated in this self-control study. The relative power and synchronization likelihood (SL) values of the electroencephalographic samples were calculated and compared off-line before and after sodium lactate infusion (0.5 M, 5 ml/kg body weight). Based on the reactivity to sodium lactate the scalp could be divided into three parts; no significant changes were seen in the seriously damaged (P3-P4) areas. The moderately affected regions in the close neighborhood showed a paradoxic inactivation with electroencephalographic slowing, a likely consequence of the metabolic-like steal effect of the near-normal areas outside. These results indicate a diminished vascular and/or metabolic reserve capacity to sodium lactate challenge in AD and confirm the formerly described electroencephalographic abnormalities.


Subject(s)
Alzheimer Disease/physiopathology , Brain/physiopathology , Electroencephalography , Sodium Lactate/pharmacology , Vasodilator Agents/pharmacology , Aged , Brain/drug effects , Cortical Synchronization , Female , Humans , Infusions, Intravenous , Likelihood Functions , Male , Scalp/physiopathology , Sodium Lactate/administration & dosage , Vasodilator Agents/administration & dosage
2.
Acta Neurol Scand ; 106(6): 392-5, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12460148

ABSTRACT

We report on three sisters with new-onset multiple sclerosis (MS). The symptoms of the eldest sister began in 1993 with lower-limb weakness and paraesthesia. In 1998, she had limb weakness, nystagmus and ataxia. Magnetic resonance imaging (MRI) of the brain, the cerebrospinal fluid (CSF) examinations, and evoked potentials verified MS. The middle sister exhibited left-side optic neuritis in 1998. All findings pointed to MS. The third sister had subjective complaints such as paraesthesias and vertigo. MRI and CSF results supported the diagnosis. Both parents and all four grandparents are without neurological signs; the brain MRI examinations on the parents were negative. The prevalence of familial MS in first-degree relatives is 5-10%, while that in twins is 20-30%. In this case, environmental factors seem to play the crucial role. Although the anamnesis as concerns MS proved negative in the other family members examined here, further genetic examination of the sisters is needed.


Subject(s)
Multiple Sclerosis/genetics , Multiple Sclerosis/pathology , Siblings , Adult , Female , Humans , Magnetic Resonance Imaging , Risk Factors
3.
Eur Neurol ; 46(4): 206-9, 2001.
Article in English | MEDLINE | ID: mdl-11721128

ABSTRACT

OBJECTIVE: The aim of this study was to determine the prevalence of multiple sclerosis (MS) in the population of Csongrád County, Hungary (400,128 inhabitants) and to determine the functional status (based on the Expanded Disability Status Scale; EDSS) of the patients according to the clinical forms of the disease. METHODS: The diagnosis was established with the aid of the Poser diagnostic criteria, and the degree of physical disability was determined using the Kurtzke EDSS. RESULTS: In Csongrád County, the prevalence of MS is 62/100,000. The distribution of patients according to the clinical forms of MS was as follows: 15% had the benign form, 54% had relapsing-remitting MS, 20% had secondary chronic progressive MS and 11% had the primary chronic progressive form of MS. Sixty percent of relapsing-remitting MS patients had an EDSS score of 0-4 points and 33% had an EDSS score of 4.5-6.5 points. CONCLUSION: The distribution of patients according to the clinical forms of the disease in this representative population is comparable to results in other regions of the world.


Subject(s)
Disability Evaluation , Multiple Sclerosis, Chronic Progressive/epidemiology , Multiple Sclerosis, Relapsing-Remitting/epidemiology , Adolescent , Adult , Aged , Cross-Cultural Comparison , Cross-Sectional Studies , Female , Humans , Hungary/epidemiology , Incidence , Male , Middle Aged , Multiple Sclerosis, Chronic Progressive/diagnosis , Multiple Sclerosis, Relapsing-Remitting/diagnosis
4.
Orv Hetil ; 140(14): 763-6, 1999 Apr 04.
Article in Hungarian | MEDLINE | ID: mdl-10224846

ABSTRACT

Interferon-beta-1b was the first drug found to slow the progression of relapsing-remitting multiple sclerosis, with a reported decrease in the relapse rate of up to 34%. The present study involved 35 patients treated with interferon-beta-1b for one year. The aims of the study were: a) to compare the changes in the relapse rate and the number of days of hospitalization with other data, b) to compare the steroid needs required to treat relapses for one year before and in the year of interferon-beta-1b treatment. Our data indicated that the relapse rate may decrease as much as 77% following the introduction of interferon-beta-1b treatment. The adverse effects and the changes in the EDSS grades were similar to the published data. The duration of hospitalization decreased by 84% and the amount of methylprednisolone needed for remission by 78%. This data suggest that the impairment of the condition of the patients may be delayed considerably, while some of them can continue to work for a longer period, the standard of life of these patients therefore being more tolerable.


Subject(s)
Interferon-beta/therapeutic use , Multiple Sclerosis/drug therapy , Humans , Interferon-beta/pharmacology , Multiple Sclerosis/physiopathology , Recurrence , Remission Induction , Treatment Outcome
5.
Acta Neurol Scand ; 99(3): 196-8, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10100965

ABSTRACT

A report is presented on a patient with Wernicke's encephalopathy secondary to hyperemesis gravidarum. The 25-year-old female presented 11 weeks into pregnancy with prolonged vomiting. Neurological examination 8 weeks later demonstrated obtunded sensations, nystagmus and ataxia of gait. MR imaging revealed bilateral lesions in the mediodorsal nuclei of thalami, in the hypothalamus and in the periaqueductal gray matter (1). The neurological signs and the MRI findings pointed to a diagnosis of Wernicke's encephalopathy. The patient was treated with intramuscular vitamin B1 followed by oral thiamine until the end of pregnancy. The subsequent course of the pregnancy was uncomplicated, and resulted in the delivery of a healthy 2970 g male infant. A review of the literature published during the last 30 years revealed an additional 20 cases of Wernicke's encephalopathy induced by hyperemesis gravidarum. Only half of these pregnancies resulted in the birth of a normal infant.


Subject(s)
Hyperemesis Gravidarum/complications , Wernicke Encephalopathy/etiology , Adult , Female , Humans , Magnetic Resonance Imaging , Pregnancy , Wernicke Encephalopathy/diagnosis
6.
Acta Neurol Scand ; 97(5): 315-9, 1998 May.
Article in English | MEDLINE | ID: mdl-9613561

ABSTRACT

OBJECTIVES: The aim of this study was to determine the prevalence of multiple sclerosis in a population in South Hungary. METHODS: The diagnosis was established with the aid of the Poser diagnostic criteria and the degree of physical disability was determined on the Kurtzke expanded disability status scale (EDSS). The present medical state (EDSS score) was determined from outpatient clinical control tests. The prevalence, the average age at onset of the disease and the proportions of the various clinical forms were calculated, and the patients' disability status was estimated. RESULTS: In 1996, the prevalence was 65/100,000, and the incidence from January 1, 1995 through December 31, 1996 was 7/100,000/year. DISCUSSION: During a period of 2 years, the number of diagnosed patients has almost doubled. The disease can be recognized in an early stage with a minimal neurological deficit. The development of the diagnostics necessitates re-examinations with modern diagnostic procedures. During the last 3 years, the general practitioner system has been reorganized, and the working relationships between the clinic and family doctors have developed considerably. A comparison of the present findings with those in other countries with a similar climate revealed very similar prevalence data.


Subject(s)
Multiple Sclerosis/epidemiology , Adult , Age of Onset , Cross-Sectional Studies , Disease Progression , Female , Humans , Hungary/epidemiology , Incidence , Male , Multiple Sclerosis/classification , Prevalence , Prospective Studies , Retrospective Studies , Sex Distribution
7.
Acta Neurol Scand ; 96(4): 236-40, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9325475

ABSTRACT

INTRODUCTION: Inflammatory processes are suspected in the pathomechanism of Alzheimer's dementia (AD) but the serum and cerebrospinal fluid (CSF) levels of inflammatory cytokines are not yet determined in the different forms of the disorder. SUBJECTS AND METHODS: Interleukin-6 (IL-6) levels were examined in the sera and CSF of patients with mild-moderate and severe stage of late onset sporadic type of AD and in the sera of demented Down syndrome (DS) probands with similar stages of AD and compared with data of age-matched healthy controls. RESULTS: Normal serum IL-6 levels were found in the mild-moderate stage, but significantly increased levels were found in the severe stage of both dementia groups. The CSF concentrations remained within the normal range in all groups. Positive correlations between the serum IL-6 levels and age and the severity of the disease were present. CONCLUSION: These findings suggest a disease stage dependent general activation of the immune system both in sporadic AD and in DS with AD.


Subject(s)
Alzheimer Disease/immunology , Dementia/immunology , Down Syndrome/immunology , Interleukin-6/blood , Aged , Alzheimer Disease/classification , Alzheimer Disease/diagnosis , Blood-Brain Barrier/immunology , Dementia/classification , Dementia/diagnosis , Diagnosis, Differential , Down Syndrome/classification , Down Syndrome/diagnosis , Female , Humans , Male , Mental Status Schedule , Middle Aged , Reference Values
9.
Orv Hetil ; 138(12): 731-7, 1997 Mar 23.
Article in Hungarian | MEDLINE | ID: mdl-9157343

ABSTRACT

Creutzfeldt-Jakob disease (CJD) is one form of subacute prion diseases with spongiform encephalopathy. Hereditary, infectious and sporadic types of the disorder can be distinguished. The abnormal transformation of the prion protein, relevant in the normal synaptic transmission is considered as an important factor in the development of this disease. Gerstmann-Sträussler-Scheinker syndrome (GSS) and familial fatal insomnia (FFI) are the other diseases belonging to the same disease spectrum. The common feature of these disorders is that the different mutation of the same prion protein could result in different phenotypes and symptoms. CJD is considered as a neurologic disorder but the clinical symptoms and differential diagnosis of the disease are also relevant problems in psychiatry. Because of the early onset of dementia and the psychotic and delusive symptoms, the patients with CJD are frequently admitted to psychiatric wards. Recently worldwide public interest has been focused on prion dementias because of the possible human transmission of bovine spongiform encephalopathy in the UK. The diagnostic problems of our seven CJD patients diagnosed since 1991 in the catchment area of Szeged city are discussed in the view of recent findings of molecular biology, nosology, diagnostic and therapeutic problems of this devastating disease.


Subject(s)
Creutzfeldt-Jakob Syndrome/diagnosis , Prion Diseases/diagnosis , Adult , Aged , Creutzfeldt-Jakob Syndrome/psychology , Diagnosis, Differential , Female , Humans , Hungary , Middle Aged , Prion Diseases/metabolism , Prion Diseases/psychology , Prions/metabolism
10.
Acta Endocrinol (Copenh) ; 104(2): 177-82, 1983 Oct.
Article in English | MEDLINE | ID: mdl-6637330

ABSTRACT

The effect of desglycinamide9-[Arg8]-vasopressin (DGAVP) on memory processes was studied in patients with Korsakoff's syndrome. Intranasal treatment with DGAVP for 7 days affected neither attention nor short- and long-term memories. It is suggested that treatment with DGAVP is not indicated for all types of memory disorders, and that the beneficial effect of this treatment may depend on the integrity of certain brain structures.


Subject(s)
Alcohol Amnestic Disorder/drug therapy , Arginine Vasopressin/analogs & derivatives , Memory/drug effects , Aged , Arginine Vasopressin/therapeutic use , Attention/drug effects , Drug Evaluation , Female , Humans , Male , Middle Aged
11.
Acta Endocrinol (Copenh) ; 102(2): 205-12, 1983 Feb.
Article in English | MEDLINE | ID: mdl-6829260

ABSTRACT

The effects of desglycinamide9-arginine8-vasopressin (DG-AVP) on memory processes have been studied in patients with central diabetes insipidus (DI) and in non-diabetic control patients. Acute im injection of DG-AVP improved some aspects of short-term memory. Subchronic intranasal administration of DG-AVP facilitated short-term memory more consistently and in addition improved long-term memory. DG-AVP increased the attention, but only in the non-diabetic subjects. The effects of DG-AVP on memory processes persisted after discontinuation of treatment. DG-AVP did not affect the parameters for water and electrolyte metabolism, blood pressure and pulse rate neither in DI nor in the control patients. Thus, the memory effects of DG-AVP are probably mediated by a direct action on the central nervous system.


Subject(s)
Arginine Vasopressin/analogs & derivatives , Diabetes Insipidus/psychology , Memory/drug effects , Adolescent , Adult , Arginine Vasopressin/pharmacology , Attention/drug effects , Female , Humans , Male , Memory, Short-Term/drug effects , Neuropsychological Tests , Psychological Tests
12.
Psychoneuroendocrinology ; 7(2-3): 185-93, 1982.
Article in English | MEDLINE | ID: mdl-7178372

ABSTRACT

Central diabetes insipidus (DI) patients showed impairments in short- and long-term memory functions, but not in attention and concentration, as compared to healthy individuals. A single i.m. injection or sub-chronic intranasal administration of either lysine-vasopressin (LVP) or 1-deamino-8-D-arginine-vasopressin (DDAVP) normalized the disturbed memory functions in DI patients. These peptides also improved memory functions in healthy individuals.


Subject(s)
Arginine Vasopressin/pharmacology , Deamino Arginine Vasopressin/pharmacology , Diabetes Insipidus/physiopathology , Lypressin/pharmacology , Memory/drug effects , Administration, Intranasal , Adult , Deamino Arginine Vasopressin/administration & dosage , Female , Humans , Injections, Intramuscular , Lypressin/administration & dosage , Male , Middle Aged
13.
Article in German | MEDLINE | ID: mdl-6800767

ABSTRACT

Continuing earlier investigation Z. EEG-EMG, 1976, 7, 151-156 the authors have studied the electrical activity of the cortex and subcortical regions elicited by stimulating mesencephalic reticular formation, after injection i.p. of Kryptopyrrole. The changes of activity was tape recorded and subjected to an off-line computer analysis with the method of Fast Fourier. Power spectral densities as well as auto and cross correlograms were calculated. The threshold for desynchronisation following stimulation shows a characteristic form due to the effect of Kryptopyrrole: after temporary decrease there is a marked increase. After stimulation the effect on subcortical structures in strikingly different from that of the cortex.


Subject(s)
Brain/drug effects , Electroencephalography/methods , Pyrroles/pharmacology , Amygdala/drug effects , Animals , Cats , Caudate Nucleus/drug effects , Cerebral Cortex/drug effects , Evoked Potentials/drug effects , Female , Hippocampus/drug effects , Male , Reticular Formation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...